{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:56:36Z","timestamp":1790830596253,"version":"4.1.0"},"reference-count":8,"publisher":"SAGE Publications","issue":"1-2","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1089\/hum.2024.53426.bfs","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T12:48:00Z","timestamp":1720529280000},"page":"7-10","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Boy Dosed with Pfizer\u2019s Duchenne Muscular Dystrophy Gene Therapy Dies a Year After Phase II Trial"],"prefix":"10.1177","volume":"36","author":[{"given":"Alex","family":"Philippidis","sequence":"first","affiliation":[{"name":"Genetic Engineering & Biotechnology News Mary Ann Liebert, Inc., publishers 140 Huguenot Street New Rochelle, NY 10801."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"e_1_3_1_2_2","unstructured":"Pfizer DMD Gene Therapy Team. Letter to Parent Project Muscular Dystrophy. May 7 2024. Available from: https:\/\/www.parentprojectmd.org\/wp-content\/uploads\/2024\/05\/Pfizer-DMD-PAG-Letter_Final.pdf [Last accessed: May11 2024]."},{"key":"e_1_3_1_3_2","unstructured":"Pfizer. U.S. FDA Approves Pfizer\u2019s BEQVEZ\u2122 (fidanacogene elaparvovec-dzkt) a One-Time Gene Therapy for Adults with Hemophilia B. April 26 2024. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/us-fda-approves-pfizers-beqveztm-fidanacogene-elaparvovec [Last accessed: May11 2024]."},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","unstructured":"Philippidis A. Regeneron Mammoth Launch In Vivo CRISPR Gene Editing Collaboration. Genetic Engineering & Biotechnology News. April 25 2024. Available from: https:\/\/www.genengnews.com\/topics\/genome-editing\/regeneron-mammoth-launch-in-vivo-crispr-gene-editing-collaboration\/ [Last accessed: May11 2024].","DOI":"10.1089\/genedge.6.01.076"},{"key":"e_1_3_1_5_2","unstructured":"Regeneron Pharmaceuticals and Mammoth Biosciences. Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases. April 25 2024. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-and-mammoth-biosciences-collaborate-pursue-next [Last accessed: May11 2024]."},{"key":"e_1_3_1_6_2","unstructured":"Regeneron Pharmaceuticals. Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks. May 8 2024. Available from: https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/latest-db-oto-results-show-dramatically-improved-hearing-normal [Last accessed: May13 2024]."},{"key":"e_1_3_1_7_2","unstructured":"Latus Bio. Latus Launches with State-of-the-Art Gene Therapy Development Technologies Two Lead Product Candidates and an Initial $54 Million in Series A Financing. May 2 2024. Available from: https:\/\/www.businesswire.com\/news\/home\/20240502968167\/en\/Latus-Launches-with-State-of-the-Art-Gene-Therapy-Development-Technologies-Two-Lead-Product-Candidates-and-an-Initial-54-Million-in-Series-A-Financing [Last accessed: May12 2024]."},{"key":"e_1_3_1_8_2","unstructured":"Bluebird Bio. Bluebird bio Announces Completion of First Cell Collection for LYFGENIA\u2122 Gene Therapy. May 6 2024. Available from: https:\/\/investor.bluebirdbio.com\/news-releases\/news-release-details\/bluebird-bio-announces-completion-first-cell-collection [Last accessed: May14 2024]."},{"key":"e_1_3_1_9_2","unstructured":"Institut de la Vision (Vision Institute) WhiteLab Genomics and ADLIN Science. GEAR: A major gene therapy. May 2 2024. Available from: https:\/\/www.institut-vision.org\/en\/news\/gear-major-gene-therapy-project [Last accessed: May12 2024]."}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2024.53426.bfs","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2024.53426.bfs","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2024.53426.bfs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:10:02Z","timestamp":1790827802000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2024.53426.bfs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":8,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1089\/hum.2024.53426.bfs"],"URL":"https:\/\/doi.org\/10.1089\/hum.2024.53426.bfs","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]}}}